[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial


Prof. Costas Hadjipanayis and Maximilien Vermandel

Mission to New York: Phase II clinical trials progress and Heliance successfully tested

A new mission organized by Hemerion in the United States enabled us to test the new version of the Heliance laser diffuser and to specify the outlines of the phase 2 trial in the treatment of glioblastoma.

After a first mission in April 2022 in Boston, the Hemerion team continues its clinical development in the USA.

During a mission to New York, several meetings with practitioners allowed us to test the new version of Heliance (laser diffuser), to discuss the implementation of phase 2 trials and to discuss the application of the Hemerion technology in new therapeutic fields.

The work program first allowed the presentation and evaluation of the new version of the Heliance diffuser, used in the treatment of glioblastoma.  Several simulator testing sessions were performed by Prof. Costas Hadjipanayis, including with the Modus V surgical robots developed by Synaptive Medical. Once again, Hemerion technologies have demonstrated a perfect integration with existing protocols.